FGF21在2型糖尿病不同体质指数患者中的表达及其与糖脂代谢的相关性研究

被引:12
作者
赵亚群
钟历勇
机构
[1] 首都医科大学附属北京天坛医院内分泌科
关键词
2型糖尿病; 成纤维细胞生长因子21; 体质指数; 糖脂代谢;
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
100201 [内科学];
摘要
目的研究血清成纤维细胞生长因子21(FGF21)在2型糖尿病不同体质指数(BMI)患者中的表达及其与糖脂代谢的相关性。方法选择2015年1月至2016年5月在首都医科大学附属北京天坛医院内分泌科住院治疗的2型糖尿病患者170例,根据BMI不同分为三组:正常组56例(BMI 18.5~24.9 kg/m2)、超重组63例(BMI25~28 kg/m2)、肥胖组51例(BMI>28 kg/m2),同期选择BMI<25 kg/m2的健康体检者30例作为对照组。采用双抗夹心酶联免疫吸附测定法检测所有受试者血清FGF21水平,同时测定受试者空腹状态下血糖、血脂、胰岛素、C肽等生化指标,并计算胰岛素抵抗指数(HOMA-IR)。运用线性相关分析血清FGF21水平与血糖、血脂、BMI、病程的关系,多元线性回归分析影响血清FGF21的影响因素。结果 2型糖尿病各亚组与健康对照组空腹血糖、糖化血红蛋白、空腹胰岛素(FIN)、HOMA-IR、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、FGF21比较差异均有统计学意义(P<0.05),2型糖尿病各亚组内比较:与BMI正常组比较,超重组FIN升高,肥胖组FIN、HOMA-IR、TG、TC、FGF21均升高(P<0.05);与超重组比较,TG、TC、FGF21均升高(P<0.05)。Spearman相关分析提示,2型糖尿病患者中血清FGF21水平与FIN(r=0.019,P=0.012)、CP(r=0.377,P<0.001)、TG(r=0.363,P<0.001)、TC(r=0.172,P=0.025)、BMI(r=0.230,P=0.002)呈正相关,与病程呈负相关(r=-0.172,P=0.025)。多元线性逐步回归分析,模型提示CP、TG与FGF21密切相关(P<0.05),标准回归方程为:YFGF21=62.475XC肽+14.263XTG+145.031(P<0.001,R2=0.12)。结论 2型糖尿病患者血清FGF21水平随着BMI的增加而上升;血清FGF21水平可能受肥胖与糖脂代谢等因素的影响。
引用
收藏
页码:3308 / 3312
页数:5
相关论文
共 14 条
[1]
成纤维细胞生长因子21在糖脂代谢和冠状动脉粥样硬化性心脏病中的研究进展 [J].
王贵丹 ;
李晓梅 ;
马依彤 .
医学综述, 2016, (01) :112-115
[2]
Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes[J] Javier Donate-Correa;Ernesto Martín-Nú?ez;Nayra Pérez Delgado;Mercedes Muros de Fuentes;Alberto Ortiz Arduan;Carmen Mora-Fernández;Juan F. Navarro González Cytokine and Growth Factor Reviews 2015,
[3]
Rapid increase in fibroblast growth factor 21 in protein malnutrition and its impact on growth and lipid metabolism[J] Yori Ozaki;Kenji Saito;Kyoko Nakazawa;Morichika Konishi;Nobuyuki Itoh;Fumihiko Hakuno;Shin-Ichiro Takahashi;Hisanori Kato;Asako Takenaka British Journal of Nutrition 2015,
[4]
Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition; adipogenesis; and adipokine secretion of human abdominal subcutaneous adipocytes[J] Lucia Berti;Martin Irmler;Marty Zdichavsky;Tobias Meile;Anja B?hm;Norbert Stefan;Andreas Fritsche;Johannes Beckers;Alfred K?nigsrainer;Hans-Ulrich H?ring;Martin Hrabě de Angelis;Harald Staiger Molecular Metabolism 2015,
[5]
The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective[J] Jian-Jun Liu;Joo Pin Foo;Sylvia Liu;Su Chi Lim Diabetes Research and Clinical Practice 2015,
[6]
Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin‐induced insulin‐deficient diabetic mice by restoring brown adipose tissue function[J] J.‐H. Kim;K.‐H. Bae;Y.‐K. Choi;Y. Go;M. Choe;Y.‐H. Jeon;H.‐W. Lee;S.‐H. Koo;J. W. Perfield;R. A. Harris;I.‐K. Lee;K.‐G. Park Diabetes Obes Metab 2015,
[7]
A non‐erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet‐induced insulin resistance in mice[J] M Collino;E Benetti;M Rogazzo;F Chiazza;R Mastrocola;D Nigro;J C Cutrin;M Aragno;R Fantozzi;M A Minetto;C Thiemermann Br J Pharmacol 2014,
[8]
Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet[J] Mingming Gao;Yongjie Ma;Ran Cui;Dexi Liu Journal of Controlled Release 2014,
[9]
Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal[J] Bo Angelin;Tobias E. Larsson;Mats Rudling Cell Metabolism 2012,
[10]
Fibroblast Growth Factor 21 (FGF-21) and Its Relation to Obesity; Metabolic Syndrome; and Nonalcoholic Fatty Liver in Children: A Longitudinal Analysis[J] Thomas Reinehr;Joachim Woelfle;Rainer Wunsch;Christian L. Roth The Journal of Clinical Endocrinology & Metabolism 2012,